Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review

P Ozieranski, L Martinon, PA Jachiet, S Mulinari - BMJ open, 2021 - bmjopen.bmj.com
Objectives To examine the accessibility and quality of drug company payment data in
Europe. Design Comparative policy review of payment data in countries with different …

[HTML][HTML] International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and …

P Ozieranski, H Saito, E Rickard, S Mulinari… - Globalization and …, 2023 - Springer
Background Self-regulation of payment disclosure by pharmaceutical industry trade groups
is a major global approach to increasing transparency of financial relationships between …

[HTML][HTML] Interaction between physicians and the pharmaceutical industry: A scoping review for developing a policy brief

E Zarei, A Ghaffari, A Nikoobar, S Bastami… - Frontiers in Public …, 2023 - frontiersin.org
Background Payments to physicians by the pharmaceutical industry are common, but recent
evidence shows that these payments influence physician prescribing behavior in the form of …

Unethical pharmaceutical marketing: a common problem requiring collective responsibility

S Mulinari, P Ozieranski - bmj, 2023 - bmj.com
Unethical pharmaceutical marketing: a common problem requiring collective responsibility | The
BMJ Skip to main content Intended for healthcare professionals Access provided by Google …

Adapting carbon neutrality: Tailoring advanced emission strategies for developing countries

F Chen, W Zhang, R Chen, F Jiang, J Ma, X Zhu - Applied Energy, 2024 - Elsevier
As global concern shifts from developed countries—many of which have made significant
strides towards carbon neutrality—to developing nations, an urgent need arises: how can …

[HTML][HTML] Pharmaceutical industry payments to NHS trusts in England: A four-year analysis of the Disclosure UK database

P Ozieranski, E Saghy, S Mulinari - Plos one, 2023 - journals.plos.org
Introduction Although hospitals are key health service providers, their financial ties to drug
companies are little understood. We examine non-research pharmaceutical industry …

[HTML][HTML] Tip of the iceberg? Country-and company-level analysis of drug company payments for research and development in Europe

P Ozieranski, L Martinon, PA Jachiet… - International Journal of …, 2022 - ncbi.nlm.nih.gov
Background: Creating new therapies often involves drug companies paying healthcare
professionals and institutions for research and development (R&D) activities, including …

[HTML][HTML] Payments reported by the pharmaceutical industry in Ireland from 2015 to 2019: an observational study

F Moriarty, J Larkin, T Fahey - Health Policy, 2021 - Elsevier
Background: The pharmaceutical industry makes large numbers of payments to healthcare
organisations (HCOs) and healthcare professionals (HCPs). Ireland has a large …

[HTML][HTML] Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019: an observational study

J Larkin, S Mulinari, P Ozieranski, K Lynch… - Health Policy and …, 2024 - Elsevier
Objective Medical device industry payments to healthcare organisations (HCOs) can create
conflicts of interest which can undermine patient care. One way of addressing this concern is …

[HTML][HTML] Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark

S Mulinari, D Pashley, P Ozieranski - Health Policy, 2022 - Elsevier
Pharmaceutical industry funding of patient organizations raises ethical challenges related to
patient engagement in healthcare due to fears of commercial agendas influencing patient …